Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Sudan war ‘being fought on women’s bodies’: Survivors detail sexual assault - 2NASA Artemis II tracker: Where is the Orion now and when will it reach the moon?
- 3Changes to CDC website spark debate over autism and vaccine misinformation
- 4Merz: 80% of Syrians in Germany expected to return within three years
- 5Sea Ice Hits New Low in Hottest Year on Record for the Arctic
- Hundreds rally in West Bank against Israeli death penalty for Palestinians
- 6 Trail blazing Bicycles for Rough terrain Undertakings
- IAF intercepts over 90% of drones launched by Iran, Hezbollah during Operation Roaring Lion
- Artemis 2 breaks humanity's all-time distance record during historic loop around the moon (video)
- Figure out How to Amplify the Resale Worth of Your Kona SUV
- The most effective method to Look at Medical caretaker Compensations Across Various Clinics
- How to see the Ursids, the final meteor shower of 2025
- The Quadrantid meteor shower peaks tonight, but will the full 'Wolf Moon' outshine the show?
- A definitive Frozen yogurt Standoff: Which Flavor Rules?
